Bridgefront Capital’s Pulmonx LUNG Stock Holding History

Bridgefront Capital’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-10,113	Closed	-$149K	–	403
2022 Q2	$149K	Buy	+10,113	New	+$208K	0.17%	246

Other funds holding LUNG

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CIP

Champlain Investment Partners Burlington, Vermont $7.88B AUM 6.82% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TCM

TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return

Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return

BNP Paribas Asset Management Paris, France $86.1B AUM 29.11% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgefront Capital's LUNG Position: Q3 2022 in Review

Bridgefront Capital sold out of Pulmonx (LUNG) in Q3 2022, closing a stake of 10,113 shares — an estimated $149K sold.

Bridgefront Capital first reported a position in LUNG in Q2 2022 and held it in 1 quarter. The position peaked at $149K in Q2 2022. 104 funds tracked by Wall St. Rank hold LUNG as of Q3 2022.

Bridgefront Capital reported no remaining Pulmonx position as of Q3 2022 after selling out during the quarter.
Bridgefront Capital sold 10,113 Pulmonx shares in Q3 2022, an estimated $149K.
Bridgefront Capital first reported a position in Pulmonx in Q2 2022 and held it in 1 quarter.
Bridgefront Capital's Pulmonx position peaked at $149K in Q2 2022.
104 funds tracked by Wall St. Rank held Pulmonx as of Q3 2022.

Based on Bridgefront Capital's 13F filing for Q3 2022, filed 29 Nov 2022.